Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gillian Powter

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Nursing Times|July 18, 2015
Nurses' role in platelet transfusion clinical trialsGillian Powter, Karen Willoughby
Trials|October 17, 2019
The TREATT Trial (TRial to EvaluAte Tranexamic acid therapy in Thrombocytopenia): safety and efficacy of tranexamic acid in patients with haematological malignancies with severe thrombocytopenia: study protocol for a double-blind randomised controlled trialLise J Estcourt, Zoe McQuilten, Gillian Powter, et al.
British Journal of Haematology|May 7, 2014
Prospective observational cohort study of the association between thromboelastometry, coagulation and platelet parameters and bleeding in patients with haematological malignancies- the ATHENA studyLise J Estcourt, Simon J Stanworth, Paul Harrison, et al.
Transfusion|April 12, 2018
Clinical bleeding and thrombin generation in admissions to critical care with prolonged prothrombin time: an exploratory studySimon J Stanworth, Michael J R Desborough, Gemma Simons, et al.
Transfusion Medicine Reviews|July 27, 2010
Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusionsSimon J Stanworth, Claire Dyer, Louise Choo, et al.
The Lancet. Rheumatology|January 22, 2024
Antibody prevalence after three or more COVID-19 vaccine doses in individuals who are immunosuppressed in the UK: a cross-sectional study from MELODYFiona A Pearce, Sean H Lim, Mary Bythell, et al.
Lancet (London, England)|January 25, 2025
Impact of SARS-CoV-2 spike antibody positivity on infection and hospitalisation rates in immunosuppressed populations during the omicron period: the MELODY studyLisa Mumford, Rachel Hogg, Adam Taylor, et al.
The New England Journal of Medicine|May 10, 2013
A no-prophylaxis platelet-transfusion strategy for hematologic cancersSimon J Stanworth, Lise J Estcourt, Gillian Powter, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Nursing Times|July 18, 2015
Nurses' role in platelet transfusion clinical trialsGillian Powter, Karen Willoughby
Trials|October 17, 2019
The TREATT Trial (TRial to EvaluAte Tranexamic acid therapy in Thrombocytopenia): safety and efficacy of tranexamic acid in patients with haematological malignancies with severe thrombocytopenia: study protocol for a double-blind randomised controlled trialLise J Estcourt, Zoe McQuilten, Gillian Powter, et al.
British Journal of Haematology|May 7, 2014
Prospective observational cohort study of the association between thromboelastometry, coagulation and platelet parameters and bleeding in patients with haematological malignancies- the ATHENA studyLise J Estcourt, Simon J Stanworth, Paul Harrison, et al.
Transfusion|April 12, 2018
Clinical bleeding and thrombin generation in admissions to critical care with prolonged prothrombin time: an exploratory studySimon J Stanworth, Michael J R Desborough, Gemma Simons, et al.
Transfusion Medicine Reviews|July 27, 2010
Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusionsSimon J Stanworth, Claire Dyer, Louise Choo, et al.
The Lancet. Rheumatology|January 22, 2024
Antibody prevalence after three or more COVID-19 vaccine doses in individuals who are immunosuppressed in the UK: a cross-sectional study from MELODYFiona A Pearce, Sean H Lim, Mary Bythell, et al.
Lancet (London, England)|January 25, 2025
Impact of SARS-CoV-2 spike antibody positivity on infection and hospitalisation rates in immunosuppressed populations during the omicron period: the MELODY studyLisa Mumford, Rachel Hogg, Adam Taylor, et al.
The New England Journal of Medicine|May 10, 2013
A no-prophylaxis platelet-transfusion strategy for hematologic cancersSimon J Stanworth, Lise J Estcourt, Gillian Powter, et al.
Pageof 1